Celyad Oncology SA (EBR:CYAD)

Celyad Oncology Statistics

Total Valuation

Celyad Oncology has a market cap or net worth of EUR 14.50 million. The enterprise value is 12.79 million.

Market Cap	14.50M
Enterprise Value	12.79M

Important Dates

The last earnings date was Thursday, April 2, 2026.

Earnings Date	Apr 2, 2026
Ex-Dividend Date	n/a

Share Statistics

Celyad Oncology has 44.76 million shares outstanding. The number of shares has increased by 11.30% in one year.

Current Share Class	44.76M
Shares Outstanding	44.76M
Shares Change (YoY)	+11.30%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	0.11%
Float	14.15M

Valuation Ratios

The trailing PE ratio is 18.00.

PE Ratio	18.00
Forward PE	n/a
PS Ratio	690.61
PB Ratio	5.95
P/TBV Ratio	5.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	15.42
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.92

Current Ratio	1.92
Quick Ratio	1.38
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-22.30

Financial Efficiency

Return on equity (ROE) is 56.33% and return on invested capital (ROIC) is -46.31%.

Return on Equity (ROE)	56.33%
Return on Assets (ROA)	-12.54%
Return on Invested Capital (ROIC)	-46.31%
Return on Capital Employed (ROCE)	-57.54%
Weighted Average Cost of Capital (WACC)	10.96%
Revenue Per Employee	4,200
Profits Per Employee	166,000
Employee Count	19
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -26.36% in the last 52 weeks. The beta is 1.22, so Celyad Oncology's price volatility has been higher than the market average.

Beta (5Y)	1.22
52-Week Price Change	-26.36%
50-Day Moving Average	0.32
200-Day Moving Average	0.28
Relative Strength Index (RSI)	50.61
Average Volume (20 Days)	15,028

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celyad Oncology had revenue of EUR 21,000 and earned 830,000 in profits. Earnings per share was 0.02.

Revenue	21,000
Gross Profit	13,000
Operating Income	-1.43M
Pretax Income	830,000
Net Income	830,000
EBITDA	-1.42M
EBIT	-1.43M
Earnings Per Share (EPS)	0.02

Balance Sheet

The company has 1.71 million in cash and n/a in debt, with a net cash position of 1.71 million or 0.04 per share.

Cash & Cash Equivalents	1.71M
Total Debt	n/a
Net Cash	1.71M
Net Cash Per Share	0.04
Equity (Book Value)	2.44M
Book Value Per Share	0.05
Working Capital	1.68M

Cash Flow

Operating Cash Flow	-6.90M
Capital Expenditures	n/a
Depreciation & Amortization	183,000
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 61.90%, with operating and profit margins of -6,795.24% and 3,952.38%.

Gross Margin	61.90%
Operating Margin	-6,795.24%
Pretax Margin	3,952.38%
Profit Margin	3,952.38%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Celyad Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.30%
Shareholder Yield	-11.30%
Earnings Yield	5.72%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celyad Oncology has an Altman Z-Score of -113.78 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-113.78
Piotroski F-Score	2